Close Menu
  • Home
  • News
  • Politics
  • Health
  • Business
  • Education
  • Opinion
  • Lifestyle
  • Entertainment
Facebook X (Twitter) Instagram
The Meridian Spy
  • Home
  • News
  • Politics
  • Health
  • Business
  • Education
  • Opinion
  • Lifestyle
  • Entertainment
The Meridian Spy
Home»News»Ghana Approves Oxford’s Malaria Vaccine For Children
News

Ghana Approves Oxford’s Malaria Vaccine For Children

meridianspyBy meridianspyApril 13, 2023No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email
Share
    

Share!

  • Share
  • Tweet

Ghana on Thursday said it is the first country in the world to approve a new malaria vaccine from Oxford University, with children under the age of three years old in line to benefit.

The mosquito-borne disease kills more than 600,000 people each year, most of them children in Africa, and scientists have been trying for years to develop vaccines.

It is unclear when the Oxford vaccine will be rolled out in Ghana.

Childhood vaccines in Africa are typically paid for by international organisations such as Gavi and UNICEF after they have been backed by the World Health Organisation (WHO), which is still assessing the vaccine’s safety and effectiveness.

First-ever crowned portrait of King Charles to feature on new Coronation coins
FG to install scanners at Abuja, Kaduna, Kano railway stations
However, Oxford scientist, Adrian Hill, said Ghana’s drug regulator has approved it for the age group at the highest risk of death from malaria, children aged 5 months to 36 months.

It has a deal with the Serum Institute of India to produce up to 200 million doses annually.

This is the first time a major vaccine has been approved first in an African country ahead of rich nations, Hill said.

It was unusual that a regulatory authority in Africa had reviewed the data quicker than the WHO, he added.

“Particularly since COVID, African regulators have been taking a much more proactive stance, they’ve been saying…we don’t want to be last in the queue,’’ Hill said.

READ ALSO  Tinubu Expresses Confidence in Kebbi Voters, Says He Can ‘Go Home and Sleep Comfortably’

The first malaria vaccine, Mosquirix from British drugmaker GSK (GSK.L), was endorsed by the WHO in 2022 after decades of work.

However, lack of funding and commercial potential thwarted the company’s capacity to produce as many doses as needed.

GSK has committed to producing up to 15 million doses of Mosquirix every year through 2028, well under the roughly 100 million doses a year of the four-dose vaccine the WHO says is needed long-term to cover around 25 million children.

Ghana, Kenya and Malawi were all involved in the pilot programme for the roll-out of Mosquirix, and have begun rolling it out more widely in recent months.

Since it began in 2019, 1.2 million children across the three countries have received at least one dose of the vaccine.

Meanwhile, the WHO said in March that in the areas where the vaccine has been given, all-cause child mortality has dropped by 10 per cent, a sign of its impact.

Mid-stage data from the Oxford vaccine trial involving more than 400 young children was published in a medical journal in September.

While the vaccine effectiveness was 80 per cent in the group that received a higher dose of the immune-boosting adjuvant component of the vaccine, and 70 per cent in the lower-dose adjuvant group, at 12 months following the fourth dose.

The doses were administered ahead of the peak malaria season in Burkina Faso.

Data from an ongoing phase III clinical trial in Burkina Faso, Kenya, Mali and Tanzania that has enrolled 4,800 children is expected to be published in a medical journal in the coming months.

READ ALSO  NITDA, DIA Explore Partnership to Develop Indigenous Defence Technology

However, late-stage data, which suggests a similar vaccine performance as in the phase II trial has been shared with regulatory authorities over the last six months, Hill said. (Reuters/NAN)

No related posts.

British drugmaker GSK
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
meridianspy

Related Posts

B’Haram Terrorists Bomb Power Transmission Towers in Niger

November 20, 2026

Shehu Dikko, Mustapha Abdullahi Lead Sports Mobilisation, Target 8 Million Votes for Tinubu/Shettima

November 20, 2026

TMS Hits 61,000 Members, Unveils National Secretariat, Plans Tinubu Presidential Library

November 20, 2026
Search
Recent Posts
  • B’Haram Terrorists Bomb Power Transmission Towers in Niger
  • Shehu Dikko, Mustapha Abdullahi Lead Sports Mobilisation, Target 8 Million Votes for Tinubu/Shettima
  • TMS Hits 61,000 Members, Unveils National Secretariat, Plans Tinubu Presidential Library
  • Obi Will Defeat APC In Anambra Despite Soludo’s Backing – Dele Momodu
  • Fidelity Bank Appoints Stanley Amuchie As New CEO
  • NITDA Urges Nigeria to Prioritise Home-Grown Technology to Build Trust in AI-Driven Future
  • JUST IN: Court Restrains Jimmy Odukoya From Presenting Himself As Senior Pastor Of Fountain Of Life Church
  • NITDA, DIA Explore Partnership to Develop Indigenous Defence Technology
  • CBN, NNPC Seal New Partnership to Strengthen Oil Revenue Management, Boost Gas Financing
  • Court Upholds Yahaya Bello’s APC Senatorial Ticket for Kogi Central
  • US Visit Not to Secure Endorsement for 2027 Presidential Bid – Obi
  • ADC-PCC Asks Tinubu to Account for $4.5m Foreign Lobbying Deal
  • Pochettino Vows to Restore Manchester United’s Dominance, Tells Fans to Give Him Time
  • JAMB to Refund UTME Registration Fees to Eligible Candidates with Disabilities
  • Tinubu Expresses Confidence in Kebbi Voters, Says He Can ‘Go Home and Sleep Comfortably’
Categories
  • Business
  • Crime
  • Education
  • Entertainment
  • Environment
  • Foreign
  • Health
  • Investigations
  • Labour
  • Lifestyle
  • Metro
  • News
  • Opinion
  • Politics
  • Security
  • Sport
  • Technology
  • World news
Access Bank DiamondXtra Season 16 Rewards
  • About us
  • Contact Us
  • News
  • Politics
  • Health
© 2026 All Right Reserved. Designed by Techjuno

Type above and press Enter to search. Press Esc to cancel.